Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 208.55B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | n/a |
| EPS (ttm) | 10.31 |
| PE Ratio | 25.20 |
| Forward PE | 12.87 |
| Dividend | 9.70 (3.51%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 10,496 |
| Average Volume | 19,344 |
| Open | 274.20 |
| Previous Close | 274.80 |
| Day's Range | 271.80 - 280.00 |
| 52-Week Range | 244.00 - 333.60 |
| Beta | 0.17 |
| RSI | 45.54 |
| Earnings Date | Jul 24, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Lomiko Metals Announces Ruisseau Graphite Project Exploration Update, La Roche Zone Extension and Fall Workplan
MONTREAL--(BUSINESS WIRE)--Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko” or the “Company”) announces exploration results from the spring program at the Ruisseau graphite prospect and plans for the summer/...
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the ...
Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...
Roche's Genentech reports positive results from lymphoma trial
Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combinati...
Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio...
Roche And Prothena: Why Moving On Makes Sense
Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue
Genentech Provides Update on Phase III Verona Study
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...
Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease - - Prasinezumab is a potential first-in-clas...
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a...
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease Prasinezumab is a potential first-in-class a...
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscu...
Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training (1) PiaSky® (crovalimab for injection) has the p...
Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems
JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed...
$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.
The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansi...
Green Steel Industry Report 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.
The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric a...
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Chugai Pharmaceutical Co. Ltd . (OTC: CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE: LLY) oral obesity pill , orforglipron. Roche Holdings AG (OTC: R...
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death com...
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy
Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature st...